Bionano Genomics Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Public

  • Employees
  • 344

Employees

  • Stock Symbol
  • BNGO

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $5.40
  • (As of Tuesday Closing)

Bionano Genomics General Information

Description

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.

Contact Information

Website
www.bionano.com
Formerly Known As
BioNanomatrix, Bionanomatrix Inc
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 9540 Towne Centre Drive
  • Suite 100
  • San Diego, CA 92121
  • United States
+1 (858)
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Stock Exchange
NAS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 9540 Towne Centre Drive
  • Suite 100
  • San Diego, CA 92121
  • United States
+1 (858)

Bionano Genomics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bionano Genomics Stock Performance

As of 11-Feb-2025, Bionano Genomics’s stock price is $5.40. Its current market cap is $12.6M with 2.33M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.40 $5.22 $4.75 - $81.00 $12.6M 2.33M 199K -$138.00

Bionano Genomics Financials Summary

As of 30-Sep-2024, Bionano Genomics has a trailing 12-month revenue of $33.3M.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 47,663 19,968 263,712 538,591
Revenue 33,334 36,116 27,802 17,981
EBITDA (118,268) (216,711) (122,081) (74,091)
Net Income (135,783) (232,493) (132,596) (72,435)
Total Assets 87,362 214,404 307,502 377,100
Total Debt 22,453 79,413 11,668 10,696
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Bionano Genomics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Bionano Genomics‘s full profile, request access.

Request a free trial

Bionano Genomics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Bionano Genomics‘s full profile, request access.

Request a free trial

Bionano Genomics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the devel
Other Healthcare Technology Systems
San Diego, CA
344 As of 2023

Marlborough, MA
 

Fremont, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bionano Genomics Competitors (38)

One of Bionano Genomics’s 38 competitors is Akoya Biosciences, a Formerly VC-backed company based in Marlborough, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Akoya Biosciences Formerly VC-backed Marlborough, MA
Cytek Formerly VC-backed Fremont, CA
10x Genomics Private Equity-Backed Pleasanton, CA
Singular Genomics Formerly VC-backed San Diego, CA
Pacific Biosciences Formerly VC-backed Menlo Park, CA
You’re viewing 5 of 38 competitors. Get the full list »

Bionano Genomics Patents

Bionano Genomics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240167957-A1 Top hat illumination biological sample imaging devices, and methods of using the same Pending 23-Nov-2022
US-20210230664-A1 Labeling of dna Pending 25-Jun-2018
EP-4159872-A1 Labeling of dna Active 25-Jun-2018
CA-3104649-A1 Labeling of dna Pending 25-Jun-2018
EP-3810801-A1 Labeling of dna Active 25-Jun-2018 C12Q1/6841
To view Bionano Genomics’s complete patent history, request access »

Bionano Genomics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bionano Genomics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Bionano Genomics‘s full profile, request access.

Request a free trial

Bionano Genomics Acquisitions (3)

Bionano Genomics’s most recent deal was a Merger/Acquisition with Purigen Biosystems for . The deal was made on 30-Nov-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Purigen Biosystems 30-Nov-2022 Merger/Acquisition Biotechnology
BioDiscovery 12-Oct-2021 Merger/Acquisition Discovery Tools (Healthcare)
Lineagen 21-Aug-2020 Merger/Acquisition Other Healthcare Technology Systems
To view Bionano Genomics’s complete acquisitions history, request access »

Bionano Genomics ESG

Risk Overview

Risk Rating

Updated April, 28, 2023

29.35 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,842

Rank

Percentile

Pharmaceuticals

Industry

of 898

Rank

Percentile

Biotechnology

Subindustry

of 402

Rank

Percentile

To view Bionano Genomics’s complete esg history, request access »

Bionano Genomics FAQs

  • When was Bionano Genomics founded?

    Bionano Genomics was founded in 2003.

  • Where is Bionano Genomics headquartered?

    Bionano Genomics is headquartered in San Diego, CA.

  • What is the size of Bionano Genomics?

    Bionano Genomics has 344 total employees.

  • What industry is Bionano Genomics in?

    Bionano Genomics’s primary industry is Other Healthcare Technology Systems.

  • Is Bionano Genomics a private or public company?

    Bionano Genomics is a Public company.

  • What is Bionano Genomics’s stock symbol?

    The ticker symbol for Bionano Genomics is BNGO.

  • What is the current stock price of Bionano Genomics?

    As of 11-Feb-2025 the stock price of Bionano Genomics is $5.40.

  • What is the current market cap of Bionano Genomics?

    The current market capitalization of Bionano Genomics is $12.6M.

  • What is Bionano Genomics’s current revenue?

    The trailing twelve month revenue for Bionano Genomics is $33.3M.

  • Who are Bionano Genomics’s competitors?

    Akoya Biosciences, Cytek, 10x Genomics, Singular Genomics, and Pacific Biosciences are some of the 38 competitors of Bionano Genomics.

  • What is Bionano Genomics’s annual earnings per share (EPS)?

    Bionano Genomics’s EPS for 12 months was -$138.00.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »